Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

UNCY Unicycive Therapeutics, Inc.

Closed 04-06 16:00:00 EDT

6.62

-0.31

-4.47%

盘后6.69

+0.07+1.06%

19:06 EDT

High7.15	Low6.51	Vol708.68K
Open6.95	D1 Closing6.93	Amplitude9.24%
Mkt Cap167.07M	Tradable Cap143.29M	Total Shares25.24M
T/O4.82M	T/O Rate3.27%	Tradable Shares21.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"UNCY","market":"US","secType":"STK","nameCN":"Unicycive Therapeutics, Inc.","latestPrice":6.62,"timestamp":1775505600000,"preClose":6.93,"halted":0,"volume":708679,"hourTrading":{"tag":"盘后","latestPrice":6.69,"preClose":6.62,"latestTime":"19:06 EDT","volume":17491,"amount":117526.3,"timestamp":1775516791053,"change":0.07,"changeRate":0.010574,"amplitude":0.049849},"delay":0,"changeRate":-0.04473304473304468,"floatShares":21645700,"shares":25237782,"eps":-1.671505,"marketStatus":"Closed","change":-0.31,"latestTime":"04-06 16:00:00 EDT","open":6.95,"high":7.15,"low":6.51,"amount":4818903.81136,"amplitude":0.092352,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.671505,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775548800000},"marketStatusCode":5,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":6.93,"preHourTrading":{"tag":"盘前","latestPrice":7.02,"preClose":6.93,"latestTime":"09:24 EDT","volume":4482,"amount":31341.702708,"timestamp":1775481894286,"change":0.09,"changeRate":0.012987,"amplitude":0.037518},"postHourTrading":{"tag":"盘后","latestPrice":6.69,"preClose":6.62,"latestTime":"19:06 EDT","volume":17491,"amount":117526.3,"timestamp":1775516791053,"change":0.07,"changeRate":0.010574,"amplitude":0.049849},"volumeRatio":1.040995,"impliedVol":2.809,"impliedVolPercentile":0.9612},"requestUrl":"/m/hq/s/UNCY","defaultTab":"news","newsList":[{"id":"2625674558","title":"Unicycive director Gaurav Aggarwal resigns from board","url":"https://stock-news.laohu8.com/highlight/detail?id=2625674558","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625674558?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:12","pubTimestamp":1775481148,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics reported resignation of director Gaurav Aggarwal from board effective April 6, 2026.Aggarwal’s departure was not tied to any disagreement with management or board on operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL8WvPqg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625567147","title":"Unicycive Therapeutics Is Maintained at Speculative Buy by Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2625567147","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625567147?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:53","pubTimestamp":1775479980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 06, 2026 08:53 ET (12:53 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676081","title":"Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676081?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:30","pubTimestamp":1775475008,"startTime":"0","endTime":"0","summary":"Benchmark lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $15 from $21 and keeps a Speculative Buy rating on the shares. After ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-15-from-21-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-15-from-21-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624029285","title":"Unicycive Therapeutics Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2624029285","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624029285?lang=en_us&edition=fundamental","pubTime":"2026-04-02 22:01","pubTimestamp":1775138460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2026 10:01 ET (14:01 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624529503","title":"Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2624529503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624529503?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:59","pubTimestamp":1775127569,"startTime":"0","endTime":"0","summary":"Guggenheim lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $40 from $46 and keeps a Buy rating on the shares. The firm made “re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-40-from-46-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-40-from-46-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624780548","title":"Unicycive publishes corporate presentation highlighting OLC NDA review ahead of June 29 PDUFA date","url":"https://stock-news.laohu8.com/highlight/detail?id=2624780548","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624780548?lang=en_us&edition=fundamental","pubTime":"2026-04-02 01:04","pubTimestamp":1775063054,"startTime":"0","endTime":"0","summary":"Unicycive highlighted oxylanthanum carbonate  as lead program for hyperphosphatemia in chronic kidney disease patients on dialysis, with NDA resubmission under FDA review.FDA assigned June 29, 2026 PDUFA date for OLC following acceptance of resubmission tied to remediation at third-party manufacturing vendor.Company positioned OLC for potential launch, citing priorities in market awareness, reimbursement access, commercial operations.Presentation cited hyperphosphatemia as US market opportunity above $1 billion, with more than 550,000 US dialysis patients.Unicycive projected cash runway into 2027 to support OLC review, potential approval, launch preparations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. pu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2n6HDD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312951","title":"Unicycive Therapeutics Q4 EPS $(0.82) Misses $0.03 Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312951","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312951?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:53","pubTimestamp":1774871623,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.82) per share which missed the analyst consensus estimate of $0.03 by 2511.76 percent. This is a 68.46 percent increase over losses of $(2.60) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51535325/unicycive-therapeutics-q4-eps-0-82-misses-0-03-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623110353","title":"Unicycive Therapeutics presentation highlights OLC NDA review for dialysis hyperphosphatemia treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2623110353","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623110353?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:15","pubTimestamp":1774869310,"startTime":"0","endTime":"0","summary":"Unicycive highlighted oxylanthanum carbonate  as lead program for hyperphosphatemia in chronic kidney disease patients on dialysis.FDA accepted OLC NDA resubmission with PDUFA date set for June 29, 2026.Resubmission followed Type A FDA meeting addressing a complete response letter deficiency tied to compliance status of a third-party manufacturing vendor.Company projected cash runway into 2027 to support potential OLC approval and launch.Pipeline update also included UNI-494 in development for acute kidney injury.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL3rtj2n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311997","title":"Press Release: Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623311997?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:05","pubTimestamp":1774868700,"startTime":"0","endTime":"0","summary":"under review by U.S. Food and Drug Administration  with a. Prescription Drug User Fee Act  target action date of June 29,-- Commercial readiness activities ongoing in anticipation of potential. securities totaled $54.9 million, with expected runway into 2027. \"This year is shaping up to be pivotal for Unicycive, underscored by the U.S. Food and Drug Administration's acceptance of our New Drug Application resubmission for OLC and the potential for approval and launch later this year,\" said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. \"With hyperphosphatemia still uncontrolled in nearly 75% of U.S. patients with chronic kidney disease undergoing dialysis, OLC, if approved, has the potential to offer a meaningful new treatment option characterized by a differentiated clinical profile and reduced pill burden compared to currently available phosphate binders.\". resubmission of its NDA for OLC, an investigational oral phosphate binder. launch of OLC later this year, the Company","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMC","IE0009354923.USD","LU2237443465.HKD","IE00BHPRN162.USD","LU1363072403.SGD","IE00BFXG1179.USD","LU0170899867.USD","LU2237443978.SGD","BK4183","BK4585","LU2237443382.USD","LU0882574139.USD","LU2237443622.USD","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","IE00BZ1G4Q59.USD","BK4006","LU2237443549.SGD","LU2746668974.SGD","BK4539","LU0971096721.USD","LU0267386448.USD","ODD","LU0149725797.USD","LU2237443895.HKD","BK4588","LABU","UNCY","LU2746668461.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623631938","title":"Unicycive FY25 net loss narrows 28% to USD 27 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623631938","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623631938?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:33","pubTimestamp":1774866799,"startTime":"0","endTime":"0","summary":"Unicycive posted a net loss of USD 27 million for fiscal 2025, narrowing 28%.Operating loss improved to USD 30 million as total operating expenses fell 8% to USD 30 million.Research and development costs dropped 54% to USD 9.1 million, while general and administrative expense climbed 69% to USD 20 million.FDA accepted the resubmitted oxylanthanum carbonate NDA as a Class II complete response, setting a PDUFA target action date of June 29, 2026.Unicycive expects current cash to fund operations for more than 12 months from the date of the report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6XxN1t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620423412","title":"Positioning Oxylanthanum Carbonate for Category-Defining Growth via TDAPA Advantage, Regulatory Clarity, and Robust Shareholder Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2620423412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620423412?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:15","pubTimestamp":1773828919,"startTime":"0","endTime":"0","summary":"Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Unicycive Therapeutics. The associated price target remains t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positioning-oxylanthanum-carbonate-for-category-defining-growth-via-tdapa-advantage-regulatory-clarity-and-robust-shareholder-returns-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positioning-oxylanthanum-carbonate-for-category-defining-growth-via-tdapa-advantage-regulatory-clarity-and-robust-shareholder-returns-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617571557","title":"Unicycive Therapeutics Publishes Corporate Presentation on Kidney Disease Pipeline and OLC Hyperphosphatemia Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2617571557","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617571557?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:58","pubTimestamp":1772747927,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc. released a corporate presentation outlining its kidney disease pipeline, led by oxylanthanum carbonate , an investigational treatment for hyperphosphatemia in chronic kidney disease patients on dialysis being developed under the FDA 505 pathway. The company said the FDA accepted its OLC NDA resubmission and assigned a PDUFA date of June 29, 2026, following a prior complete response letter tied to third-party manufacturing vendor compliance. The presentation also highlighted launch readiness priorities, including market awareness, reimbursement, and commercial logistics, and noted UNI-494 in development for acute kidney injury. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL6KxPd8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616386536","title":"Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616386536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616386536?lang=en_us&edition=fundamental","pubTime":"2026-03-02 15:26","pubTimestamp":1772436409,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Unicycive Therapeutics on February 27 and set a price target of $90.00. The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-unicycive-therapeutics-uncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-unicycive-therapeutics-uncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612607222","title":"Unicycive Therapeutics management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2612607222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612607222?lang=en_us&edition=fundamental","pubTime":"2026-02-20 22:22","pubTimestamp":1771597343,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on February 25 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612407075","title":"Unicycive Therapeutics initiated with a Buy at WestPark Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2612407075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612407075?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:57","pubTimestamp":1771505858,"startTime":"0","endTime":"0","summary":"WestPark Capital initiated coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $72 price target Given the view that a significant numbe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-initiated-with-a-buy-at-westpark-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-initiated-with-a-buy-at-westpark-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612507634","title":"Unicycive Therapeutics Faces Shareholder Lawsuit Over Alleged False Statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2612507634","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612507634?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:16","pubTimestamp":1771337760,"startTime":"0","endTime":"0","summary":"Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics Inc., alleging that certain officers and directors breached their fiduciary duties. The investigation centers on accusations that the company overstated its readiness to meet FDA manufacturing compliance requirements and exaggerated the regulatory prospects of its oxylanthanum carbonate new drug application, resulting in potentially false and misleading public statements. Shareholders who purchased shares before March 29, 2024, and still hold them may seek corporate reforms and the return of funds to the company.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL4Fmyfg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609251974","title":"Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and Launch Plans for OLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2609251974","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609251974?lang=en_us&edition=fundamental","pubTime":"2026-02-07 04:53","pubTimestamp":1770411189,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc. has released a corporate presentation highlighting its progress in developing novel treatments for kidney disease. The company’s lead asset, oxylanthanum carbonate , is under review by the FDA for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The New Drug Application  for OLC was resubmitted following resolution of manufacturing-related issues, and the FDA has set a Prescription Drug User Fee Act  date of June 29, 2026. Unicycive reports an expanded market opportunity for OLC, citing recent developments in the reimbursement landscape. The presentation also notes that the company’s pipeline includes UNI-494, in development for acute kidney injury and chronic kidney disease. The company states it has a cash runway into 2027 to support its ongoing development and potential commercial activities. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL16Mhk1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608361393","title":"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2608361393","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608361393?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:05","pubTimestamp":1770206700,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3231919/0/en/Unicycive-Therapeutics-to-Participate-in-a-Fireside-Chat-at-Guggenheim-s-Emerging-Outlook-Biotech-Summit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0009354923.USD","BK4588","BK4183","UNCY","BK4211","SMMF","ODD","BK4539","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607493029","title":"Unicycive Therapeutics Showcases Pipeline Advancements in Kidney Disease Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2607493029","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607493029?lang=en_us&edition=fundamental","pubTime":"2026-01-31 04:47","pubTimestamp":1769806034,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc. has released a corporate presentation detailing its progress in developing novel treatments for kidney diseases. The company’s lead asset, oxylanthanum carbonate , is being advanced for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The OLC New Drug Application  was resubmitted to the FDA following the resolution of a manufacturing-related deficiency, and the FDA has assigned a PDUFA date of June 29, 2026. Unicycive reports a cash runway extending into 2027 to support the application resubmission, potential FDA approval, and commercial launch activities. The company also highlights ongoing development of UNI-494, targeting acute kidney injury and chronic kidney disease. OLC is being developed under the FDA’s 505 regulatory pathway and, if approved, will offer a formulation that is swallowed whole, differing from the reference-listed drug Fosrenol. The presentation notes that the market opportunity for hyperphosphatemia tre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL672g6d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607412870","title":"Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607412870","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607412870?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:40","pubTimestamp":1769784027,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Protagonist Therapeutics (PTGX – Research Report) an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-protagonist-therapeutics-ptgx-and-unicycive-therapeutics-uncy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-protagonist-therapeutics-ptgx-and-unicycive-therapeutics-uncy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4585","BK4581","XBI","BK4139","LABU","LU0029874061.USD","LU0128526141.USD","PTGX","HCSG","UNCY","BK4137","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unicycive.com","stockEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0221},{"period":"3month","weight":0.1948},{"period":"6month","weight":0.5},{"period":"1year","weight":0.2634},{"period":"ytd","weight":0.201}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.078139},{"month":2,"riseRate":0.6,"avgChangeRate":0.088088},{"month":3,"riseRate":0.4,"avgChangeRate":0.59683},{"month":4,"riseRate":0.4,"avgChangeRate":-0.141558},{"month":5,"riseRate":0.5,"avgChangeRate":-0.066545},{"month":6,"riseRate":0,"avgChangeRate":-0.181228},{"month":7,"riseRate":0,"avgChangeRate":-0.103059},{"month":8,"riseRate":0.2,"avgChangeRate":-0.122604},{"month":9,"riseRate":0.6,"avgChangeRate":0.038818},{"month":10,"riseRate":0.8,"avgChangeRate":0.050976},{"month":11,"riseRate":0.6,"avgChangeRate":0.060673},{"month":12,"riseRate":0.4,"avgChangeRate":0.09852}],"exchange":"NASDAQ","name":"Unicycive Therapeutics, Inc.","nameEN":"Unicycive Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Unicycive Therapeutics, Inc.,UNCY,Unicycive Therapeutics, Inc.股票,Unicycive Therapeutics, Inc.股票老虎,Unicycive Therapeutics, Inc.股票老虎国际,Unicycive Therapeutics, Inc.行情,Unicycive Therapeutics, Inc.股票行情,Unicycive Therapeutics, Inc.股价,Unicycive Therapeutics, Inc.股市,Unicycive Therapeutics, Inc.股票价格,Unicycive Therapeutics, Inc.股票交易,Unicycive Therapeutics, Inc.股票购买,Unicycive Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}